|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
The clinical application of camrelizumab on advanced hepatocellular carcinoma
Zhongguang Chen , Xiuhua Lu & Kelly Koral
Received 20 May 2020, Accepted 06 Aug 2020, Accepted author version posted online: 07 Aug 2020
Download citation https://doi.org/10.1080/17474124.2020.1807939 CrossMark Logo CrossMark
Accepted author version
Abstract
Introduction
Camrelizumab (also known as SHR-1210), a humanised monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and consequently inhibit the immune escape of tumour cells. Recently, camrelizumab was approved as a second-line drug for previously treated advanced hepatocellular carcinoma in China.
Areas covered
In this paper, the chemical properties, mechanism of action, pharmacokinetics, clinical efficacy, safety and tolerability of camrelizumab for the treatment of advanced hepatocellular carcinoma are introduced in detail. The strategy for combination therapy and the potential application of camrelizumab in other solid tumours are briefly described. We performed a systematic review of the literature in PubMed and the following keywords were used: “SHR-1210”, “Camrelizumab” and “hepatocellular carcinoma”.
Expert opinion
Camrelizumab is a selective, humanised, high-affinity IgG4 kappa mAb against PD-1. Camrelizumab showed promising antitumour activity and manageable toxicities and offers a new second-line drug option for patients with advanced hepatocellular carcinoma. Reactive cutaneous capillary endothelial proliferation is a novel but prevalent immune-related dermatologic toxicity of camrelizumab, which is mild, reversible, and predictable. More clinical trials of camrelizumab are ongoing to develop combination therapy strategies and new indications for malignancies.
Keywords: advanced hepatocellular carcinoma, camrelizumab, PD-1, SHR-1210, immunotherapy
Additional information
Funding
This paper was funded by the Key Research & Development Program of Shandong Province (2018GGX109006).
Article Highlights
● Camrelizumab is a selective, humanised, high-affinity IgG4 kappa mAb against PD-1.
● Camrelizumab binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, thus blocking immunosuppression mediated by the PD-1 pathway including antitumour immune response, resulting in anti-tumour activity.
● Camrelizumab was approved as a second-line drug by the NMPA for the treatment of patients with advanced HCC, who have previously received sorafenib treatment and/or oxaliplatin systemic chemotherapies.
● Recommended dosage of camrelizumab for advanced HCC patients: 3 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity.
● Camrelizumab is well tolerated with a manageable toxicity profile. Most frequent AEs are RCCEP, anaemia, fever, fatigue, hypothyroidism, proteinuria, cough and decreased appetite.
Declaration of interest
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.
|
|
发表于 2020-8-8 21:57